
Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

Faculty weigh the new class-wide blood pressure warning and why dropping the age-related limitation treats low testosterone as a syndrome, not aging.

Expert urologists argue that testosterone is an underused biomarker of men’s health, and review how TRAVERSE resolved longstanding cardiovascular safety concerns.

FDA expert panel members review how TRAVERSE and new evidence prompted testosterone label revisions, and what they mean for treating deficiency.

Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.

November 16th 2026

November 16th 2026

November 18th 2026